NOV 03, 2016 09:00 AM PDT

Risk Mitigation and Management to ensure Virus Safety of Biopharmaceuticals: Regulatory Perspectives and Industry Best Practices

SPONSORED BY: Sartorius, Sartorius
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Field Marketing Manager
    Biography
      Hazel Aranha is a biopharmaceutical industry professional with over 30 years' experience in industry, academia and consulting. She is a well-acknowledged expert in the area of virus and prion clearance from biopharmaceuticals. She has provided consulting services in the US, Europe and Asia. She teaches courses on ‘ensuring virus safety of biologicals', as well as other topics including: ‘Good Clinical Practices' (GCP), ‘Good Manufacturing Practices (GMP), ‘Downstream Processing', ‘Navigating the Drug Development Cycle', and ‘Effective Biomedical Writing'.
      Hazel has a Master's degree in Virology, Ph.D. in Environmental Microbiology and holds Regulatory Affairs Certification (RAC) for both the US and European Union. She has to her credit 2 books, over 45 publications, and 4 book chapters. Her past assignments have included positions at Catalent Pharma Solutions, Wyeth Vaccines (Pfizer), and Pall Corporation.

    Abstract:
    DATE: November 3, 2016
    TIME:  9:00AM PT, 12:00PM ET


    Patient safety is at the core of biopharmaceutical manufacturing operations. Ensuring virus safety of biopharmaceutical products poses logistical challenges for several reasons including: nature of raw materials, non-homogenous distribution of raw materials, and limitations with virus detection methods.
    This webinar will address the regulatory basics in virus safety assurance, the need for incorporation of multiple orthogonal virus clearance strategies, and design of validation studies. Case studies will be presented to demonstrate industry best practices. In addition to risk management in downstream operations, the importance of risk mitigation in upstream operations to minimize bioreactor contamination events will be discussed.

    Learning Objective 1:  Learn about the  regulatory basics in virus safety assurance of biopharmaceutical products.

    Learning Objective 2:  Learn about common virus clearance technologies used in the biopharmaceutical industry.
     

    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    APR 26, 2018 07:30 AM PDT
    C.E. CREDITS
    APR 26, 2018 07:30 AM PDT
    DATE: April 26, 2018TIME: 07:30am PDT, 04:30pm CESTThe NGS library preparation process is labor-intensive, requiring experience and attention to detail over hours. Eppendorf consumables...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    Loading Comments...